http://www.currentpartnering.com/2012/02/06/partnering-2011-leading-deals-by-upfront-payment-another-measure-of-deal-value-to-the-licensee/
This article contains a useful perspective on licence deals and how much a partner really values the assets they are licensing. Not strictly relevant to PYC other than pointing out you get a lot more for licensing drug candidates, as compared with drug/peptide discovery deals. Would be nice if PYC would do something with their CD40 peptides (tox. studies, Phase 1 trial etc), as this would enhance the value of the whole library by demonstrating that phylomers could be drugs in their own right.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
0.000(0.00%) |
Mkt cap ! $839.8M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.45 | $1.42 | $3.475M | 2.414M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 55564 | $1.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 6099 | 3 |
View Market Depth
| Last trade - 16.10pm 11/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |